Best of ASCO - 2014 Annual Meeting

 

Welcome

Acute Leukemia

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2017 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A Bayesian randomized phase II study of guadecitabine (SGI-110) based regimens comparing guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + idarubicin (SGI5 + Ida), 5 days + cladribine (SGI5 + Clad), in untreated patients ≥ 70 years with acute myeloid leukemia (AML).

Kiran Naqvi

7019

A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Rachel J. Cook

TPS7071

A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy.

Margaret T. Kasner

7043

A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.

Norbert Vey

TPS7070

A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.

Jorge E. Cortes

TPS7068

A single center experience with two decades of follow-up on patients with hairy cell leukemia.

Osman Ilhan

e18530

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse.

Prajwal Boddu

7018

An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.

Alexander E. Perl

TPS7067

Association of CDKN2A/2B deletion with homozygous deletion of TCR- γ gene in T-ALL.

Anita Chopra

e18516

Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL.

Jae Hong Park

7024

BST-236

Tsila Zuckerman

e18520

Burden of illness in patients with acute myeloid leukemia aged ò65 years ineligible for intensive chemotherapy.

Marie-Helene Lafeuille

e18529

CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).

Eunice S. Wang

TPS7066

CD19 targeted chimeric antigen receptor T (CAR-T) cell immunotherapy has demonstrated significant anti-leukemia activity in pediatric patients with relapsed/refractory acute lymphocytic leukemia: A multicentre study in China.

Lei Xiao

e18512

Clinical observations of AML expressing mutant RUNX1 and pre-clinical studies of RUNX1-targeted novel therapy of AML.

Courtney Denton Dinardo

7030

Clinical utilization of the Myeloid Malignancies Mutation Panel.

Saad A Arain

e18523

Clostridium difficile infection in acute myeloid leukemia patients.

Anjali Bal

e18503

Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

Gunhan Gurman

e18518

Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.

Koichi Takahashi

7034

Cost of care for adult patients with relapsed acute lymphoblastic leukemia (rALL) in Germany.

Yun Su

e18504

Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML).

Donald A. Berry

7021

CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML).

Victoria Wang

7040

Cytogenetic evolution between diagnosis and relapse and impact on acute myeloid leukemia (AML) reinduction outcomes.

Andrew Mark Brunner

e18509

Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

Jessica K. Altman

7003

Determinants of quality of life in patients with acute myeloid leukemia.

Sarah A. Buckley

e18528

Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2).

Amir Tahmasb Fathi

7015

Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML.

Koichi Takahashi

7005

Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Harry Paul Erba

7027

Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy.

Jae Hong Park

7008

Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.

Richard M. Stone

7016

Effect of echocardiogram prior to induction therapy for acute myeloid leukemia on detection of cardiac dysfunction and treatment modifications.

Jennifer C. Yui

e18514

Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Jonathan E. Kolitz

7036

Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.

Lei Xiao

7028

Efficacy of clofarabine and low-dose cytarabine combination for genetically high-risk acute myeloid leukemia prior to allogeneic stem cell transplantation.

Carlos Enrique Vigil

e18515

Emotion and Symptom-focused Engagement (EASE): A randomized pilot trial of an integrated psychosocial and palliative care intervention for individuals with acute leukemia (AL).

Gary Rodin

7041

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

Eytan M. Stein

7004

Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from a randomized phase III study.

Anthony Selwyn Stein

7032

Flow cytometry minimal residual disease assessment in peripheral blood of adult acute lymphoblastic leukemia patients.

Alissa Minkovsky

e18517

Frequency of target attainment and toxicity with reduced PEG-asparaginase (PEG) dosing in acute lymphoblastic leukemia (ALL).

Mitchell Streck

e18501

Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.

Nicholas James Short

7013

Genomic landscape of adult mixed phenotype acute leukemia (MPAL).

Kiyomi Morita

7023

Hematopoietic cell transplant comorbidity index (HCT-CI) to assess AML induction risk.

Martin W. Schoen

e18519

Hospital readmission rate for febrile neutropenia (FN) following high dose cytarabine (HiDAC) consolidation chemotherapy for acute myeloid leukemia (AML).

Caitlin Siebenaller

e18513

Hospitalization for patients in the United States (US) and European Union (EU) treated with inotuzumab ozogamicin (InO) vs standard of care (SOC) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in a global phase 3 trial.

Yun Su

e18500

Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study.

Ghayas C. Issa

7037

Immune-related gene expression deficit of leukemia stem cells (LSC) in AML.

Kamal Chamoun

7011

Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).

Rita Assi

7025

Method for definition of CIS-TRANS status in double CEBPA mutations.

Miguel Mitne-Neto

e18511

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.

Daniel Aaron Pollyea

7022

Neutropenic fever prophylaxis during induction therapy for acute myeloid leukemia.

Nassim H. Nabbout

e18531

Outcomes in AML patients age ≥70: A very large single institution experience.

Jeffrey E. Lancet

7031

Outcomes with lower intensity therapy in TP53-mutated AML.

Tapan M. Kadia

7017

Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Bruno C. Medeiros

e18507

Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.

Jeffrey E. Lancet

7035

Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia.

Jalaja Potluri

TPS7069

Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS.

Christopher Brent Benton

e18521

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

Naval Guastad Daver

e18505

Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.

Naval Guastad Daver

7026

Prognostic significance of alterations of pathways regulating autophagy in Acute Myeloid Leukemia.

Giovanni Marconi

7038

Quality of life of acute myeloid leukemia patients in a real-world setting.

Bhavik J. Pandya

e18525

Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Ilse van Oostrum

e18506

Real world patient numbers for AML targeted therapies.

Marcos Tadeu dos Santos

e18510

Real-world prescribing patterns in acute myeloid leukemia in the United States.

Bruno C. Medeiros

e18524

Response and survival rates with frontline hypomethylating agent (HMAs) in favorable risk AML.

Michael Richard Grunwald

7039

Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.

Maro Ohanian

7029

Stroma-free long-term growth of primary acute myeloid leukemia (AML) cells.

Jing Chen

e18535

Systematic literature review and indirect treatment comparisons (ITC) of glasdegib (GLAS) plus low dose ara-c (LDAC) versus a hypomethylating agent (HMA) for previously untreated acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy (NIC).

Anna Forsythe

e18526

Treatment of adolescents and young adults with Philadelphia negative acute lymphoblastic leukemia (AYA Ph-ALL) using a risk and response based protocol with extended intensification and high dose methotrexate: A report from a single center in Saudi Arabia.

Saleem Eldadah

e18527

Treatment patterns and characteristics of acute promyelocytic leukemia (APL) patients receiving arsenic trioxide (ATO) therapy in a real-world setting.

Boxiong Tang

e18522

Unsupervised hierarchical clustering of surface antigen expression to identify normal karyotype AML patients with distinct disease characteristics and poor outcome.

Madlen Jentzsch

7042

Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.

Nicholas James Short

7014

Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia.

Abhishek Maiti

7033

Volumetric modulated arc therapy versus conformal radiation therapy for conditioning of allogenic bone marrow transplantation (ABMT) in acute lymphoblastic leukemia.

María Fátima Chilaca Rosas

e18532